Answers are grounded in this paper and cite their sources.
Background/Aims: Phosphatase and tensin homolog (PTEN) is a known tumor suppressor gene that is downregulated in hepatocellular carcinoma (HCC).Here, we investigated the association between single nucleotide polymorphisms (SNPs) of PTEN and HCC development in patients with hepatitis B virus (HBV) infection.Methods: Six SNPs of PTEN at positions rs1234221, rs1903860, rs1234220, rs1903858, rs2299941, and rs17431184 were analyzed in a development population (417 chronic HBV carriers without HCC and 281 chronic HBV carriers with HCC).PTEN rs1903858, rs1903860, and rs2299941 SNPs were further assessed for the development of HCC in a validation population of 200 patients with HBV-related liver cirrhosis.Results: In the development population, PTEN rs1903860 C allele, rs1903858 G allele, and rs2299941 G allele were associated with a low risk of HCC.The haplotype A-T-A-A-A was associated with an increased risk of HCC (recessive model; odds ratio=2.277,95% confidence interval [CI] =1.144-4.532,P=0.019).In the validation population, PTEN rs2299941 G allele was the only significant protective genetic polymorphism related to HCC development after adjustment for age and sex (hazard ratio=0.582,95% CI =0.353-0.962,P=0.035).Conclusions: These findings suggest that genetic polymorphisms in PTEN may affect HCC development in patients with chronic HBV infection.(J Liver Cancer 2019;19:46-54)
No takes yet. Share an insight, caveat, or question.
Kim et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: